Athira Pharma, Inc. Financials
This page shows Athira Pharma, Inc. (ATHA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is carrying the balance sheet while operations continue consuming cash and equity shrinks.
Earnings quality diverged from cash usage in FY2025: net loss reached-$106M , but operating cash flow was-$45.7M . That gap suggests substantial non-cash charges or timing effects in reported earnings, rather than the income statement translating directly into cash consumption.
Liquidity improved only through financing rather than operations. Cash rose from
The financing structure became materially less forgiving. Total liabilities increased from
Financial Health Signals
Athira Pharma, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Athira Pharma, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Athira Pharma, Inc. reported a net loss of $106.0M while operations used $45.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Athira Pharma, Inc.'s EBITDA was -$101.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.4% from the prior year.
Athira Pharma, Inc. reported -$106.0M in net income in fiscal year 2025. This represents a decrease of 9.3% from the prior year.
Athira Pharma, Inc. earned -$24.70 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Athira Pharma, Inc. held $69.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Athira Pharma, Inc.'s ROE was -381.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 165.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Athira Pharma, Inc. invested $17.5M in research and development in fiscal year 2025. This represents a decrease of 75.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ATHA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $17.5M-75.2% | $70.7M-24.6% | $93.8M+52.6% | $61.5M+43.6% | $42.8M+222.1% | $13.3M+250.3% | $3.8M |
| SG&A Expenses | N/A | $16.7M-36.1% | $26.1M-21.7% | $33.3M+2.3% | $32.6M+53.3% | $21.2M+216.4% | $6.7M+305.1% | $1.7M |
| Operating Income | N/A | -$102.3M-1.4% | -$100.9M+19.6% | -$125.5M-20.6% | -$104.0M-62.5% | -$64.0M-220.2% | -$20.0M-266.9% | -$5.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $3K-99.2% | $367K+6.1% | $346K |
| Income Tax | N/A | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$106.0M-9.3% | -$97.0M+17.6% | -$117.7M-23.0% | -$95.6M-74.4% | -$54.9M-174.9% | -$20.0M-286.6% | -$5.2M |
| EPS (Diluted) | — | -$24.70 | -$25.19 | -$3.09-22.1% | -$2.53-69.8% | -$1.49 | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ATHA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $92.2M+56.8% | $58.8M-63.3% | $160.2M-37.9% | $258.2M-22.2% | $332.0M+18.8% | $279.6M+12671.3% | $2.2M |
| Current Assets | $89.5M+63.1% | $54.8M-64.6% | $154.7M-25.4% | $207.5M-20.4% | $260.8M+35.6% | $192.3M+8804.5% | $2.2M |
| Cash & Equivalents | $69.3M+43.0% | $48.4M-46.5% | $90.6M-5.6% | $96.0M-13.2% | $110.5M+82.3% | $60.6M+2848.7% | $2.1M |
| Total Liabilities | $64.4M+361.8% | $13.9M-53.6% | $30.1M+30.6% | $23.0M+110.7% | $10.9M+106.9% | $5.3M-75.9% | $21.9M |
| Current Liabilities | $47.5M+261.7% | $13.1M-54.5% | $28.8M+34.6% | $21.4M+130.6% | $9.3M+110.9% | $4.4M+246.0% | $1.3M |
| Total Equity | $27.8M-38.0% | $44.8M-65.6% | $130.2M-44.6% | $235.1M-26.8% | $321.1M+17.1% | $274.3M+1490.7% | -$19.7M |
| Retained Earnings | -$511.8M-26.0% | -$406.1M-31.4% | -$309.2M-61.4% | -$191.5M-99.7% | -$95.9M-133.7% | -$41.0M-94.6% | -$21.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ATHA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$52.0M | -$45.7M+52.9% | -$97.2M+3.6% | -$100.8M-39.0% | -$72.5M-68.1% | -$43.1M-78.7% | -$24.1M-549.4% | -$3.7M |
| Capital Expenditures | N/A | N/A | $33K-89.1% | $304K-73.4% | $1.1M-27.5% | $1.6M-32.2% | $2.3M | N/A |
| Free Cash Flow | N/A | N/A | -$97.2M+3.8% | -$101.1M-37.3% | -$73.6M-64.8% | -$44.7M-69.0% | -$26.4M | N/A |
| Investing Cash Flow | -$24.1M | -$15.9M-129.0% | $54.8M-42.3% | $95.1M+64.9% | $57.7M+1513.7% | -$4.1M+98.1% | -$210.1M-14048.7% | $1.5M |
| Financing Cash Flow | N/A | $82.5M+42405.7% | $194K-60.6% | $493K-24.6% | $654K-99.3% | $97.1M-66.8% | $292.8M+30846.1% | $946K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ATHA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Return on Equity | -381.4%-165.1pp | -216.3%-125.9pp | -90.4%-49.7pp | -40.7%-23.6pp | -17.1%-9.8pp | -7.3% | N/A |
| Return on Assets | -115.0%+50.0pp | -165.0%-91.6pp | -73.4%-36.4pp | -37.0%-20.5pp | -16.5%-9.4pp | -7.1%+228.6pp | -235.8% |
| Current Ratio | 1.88-2.3x | 4.18-1.2x | 5.37-4.3x | 9.68-18.4x | 28.07-15.6x | 43.66+42.0x | 1.70 |
| Debt-to-Equity | 2.32+2.0x | 0.31+0.1x | 0.23+0.1x | 0.10+0.1x | 0.030.0x | 0.02 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Athira Pharma, Inc. Ranks
Frequently Asked Questions
Is Athira Pharma, Inc. profitable?
No, Athira Pharma, Inc. (ATHA) reported a net income of -$106.0M in fiscal year 2025.
What is Athira Pharma, Inc.'s EBITDA?
Athira Pharma, Inc. (ATHA) had EBITDA of -$101.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Athira Pharma, Inc.'s return on equity (ROE)?
Athira Pharma, Inc. (ATHA) has a return on equity of -381.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Athira Pharma, Inc.'s operating cash flow?
Athira Pharma, Inc. (ATHA) recorded an outflow of $45.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Athira Pharma, Inc.'s total assets?
Athira Pharma, Inc. (ATHA) had $92.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Athira Pharma, Inc. spend on research and development?
Athira Pharma, Inc. (ATHA) invested $17.5M in research and development during fiscal year 2025.
What is Athira Pharma, Inc.'s current ratio?
Athira Pharma, Inc. (ATHA) had a current ratio of 1.88 as of fiscal year 2025, which is generally considered healthy.
What is Athira Pharma, Inc.'s debt-to-equity ratio?
Athira Pharma, Inc. (ATHA) had a debt-to-equity ratio of 2.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Athira Pharma, Inc.'s return on assets (ROA)?
Athira Pharma, Inc. (ATHA) had a return on assets of -115.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Athira Pharma, Inc.'s cash runway?
Based on fiscal year 2025 data, Athira Pharma, Inc. (ATHA) had $69.3M in cash against an annual operating cash burn of $45.7M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Athira Pharma, Inc.'s Piotroski F-Score?
Athira Pharma, Inc. (ATHA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Athira Pharma, Inc.'s earnings high quality?
Athira Pharma, Inc. (ATHA) reported a net loss of $106.0M while operations used $45.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.